|Over a month ago|
Vanda Pharma closes enrollment in ODYSSEY study » 07:2708/0308/03/21
Vanda Pharmaceuticals announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met the pre-defined futility criteria, indicating that the study was unlikely to succeed in its pre-specified primary endpoint. The study was designed to determine whether tradipitant plus standard of care is superior to placebo plus standard of care in treating hospitalized patients with COVID-19 pneumonia who required supplemental oxygen support. The primary endpoint of the study is the difference between treatment and placebo on time to 2-point improvement on a 7-point ordinal scale. Treatment duration was 14 days and evaluation for the primary endpoint was at Day 28. Additional secondary endpoints include other changes in clinical and laboratory status.
Vanda Pharmaceuticals sees FY21 revenue $270M-$300M, consensus $282.92M » 17:0307/2807/28/21
Sees year end cash…
Sees year end cash greater than $400M.
Vanda Pharmaceuticals reports Q2 EPS 17c, consensus 14c » 17:0207/2807/28/21
Reports Q2 revenue…
Reports Q2 revenue $67.9M, consensus $69.75M. "Vanda had another outstanding quarter of commercial revenue growth as we resumed activity across a number of our clinical programs. Our tradipitant in gastroparesis program is nearing completion, bringing us closer to a much-needed new treatment option for patients with gastroparesis and a potentially transformational commercial opportunity for Vanda," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board.
|Over a quarter ago|
Fly Intel: Top five analyst initiations » 09:5605/1205/12/21
TSP, VNDA, NYMT, CCEP, ASPN
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. TuSimple (TSP) initiated with an Outperform at Credit Suisse. 2. Vanda Pharmaceuticals (VNDA) initiated with a Buy at BofA. 3. New York Mortgage (NYMT) initiated with a Buy at B. Riley. 4. Coca-Cola European Partners (CCEP) reinstated with a Neutral at Goldman Sachs. 5. Aspen Aerogels (ASPN) assumed with an Outperform at Northland. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BofA starts 'multi-product pipeline play' Vanda Pharmaceuticals at Buy » 07:2905/1205/12/21
As previously reported,…
As previously reported, BofA analyst Olivia Brayer initiated coverage of Vanda Pharmaceuticals with a Buy rating and $22 price target. Vanda is a CNS-focused biopharma company with two core assets, Fanapt and Hetlioz, that is already profitable and is now transitioning to "a multi-product pipeline play" with over six phase 3 programs ranging from label expansions and newer pipeline products, Brayer tells investors. Vanda tends to "fly under the radar given past regulatory setbacks," but it is now in a good position for what should be a turning point in the story into the second half of 2021, Brayer argues.
Vanda Pharmaceuticals initiated with a Buy at BofA » 06:0405/1205/12/21
BofA initiated coverage…
BofA initiated coverage of Vanda Pharmaceuticals with a Buy rating and $22 price target.
Vanda Pharmaceuticals sees FY21 revenue $270M-$300M, one estimate $283.4M 16:2805/0505/05/21
Vanda Pharmaceuticals reports Q1 EPS 15c, one estimate 15c » 16:2705/0505/05/21
Reports Q1 revenue…
Reports Q1 revenue $62.7M, one estimate $68.5M.Cash, cash equivalents and marketable securities was $378.2M as of March 31, representing an increase to cash of $65.8M a year ago. "Despite seasonal and global challenges, we recorded another quarter of strong revenue across our commercial portfolio coupled with the launch of Hetlioz in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome," said Mihael Polymeropoulos. "In our clinical programs, we have made significant progress, reaching 85% randomization in our Phase III tradipitant study in gastroparesis and initiating a new clinical program for Hetlioz in delayed sleep phase disorder."
Vanda Pharmaceuticals price target raised to $18 from $14 at Citi » 06:2502/1102/11/21
Citi analyst Joel Beatty…
Citi analyst Joel Beatty raised the firm's price target on Vanda Pharmaceuticals to $18 from $14 and keeps a Neutral rating on the shares following the company's Q4 results. The most notable takeaway from earnings is new financial guidance for 2021, which includes guidance for year-end cash of greater than $400M, Beatty tells investors in a research note. The analyst believes this suggests a "meaningful commitment to keep opex controlled during 2021." He also increased the probability of approval of tradipitant for gastroparesis to 30% from 10%.
Vanda Pharmaceuticals downgraded to Neutral from Buy at Citi » 06:3201/1401/14/21
Citi analyst Joel Beatty…
Citi analyst Joel Beatty downgraded Vanda Pharmaceuticals to Neutral from Buy with an unchanged price target of $14. The stock is up 50% since September, with relatively little change to the company's fundamental value, Beatty tells investors in a research note. The analyst anticipates "relatively little downside" to Vanda shire over the coming months but also "relatively little upside."